Wall Street brokerages expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce ($0.87) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Voyager Therapeutics’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.69). Voyager Therapeutics posted earnings of ($0.63) per share during the same quarter last year, which indicates a negative year over year growth rate of 38.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($3.92) to ($1.29). For the next year, analysts anticipate that the firm will post earnings of ($2.68) per share, with EPS estimates ranging from ($4.99) to ($1.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $1.17. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The firm had revenue of $46.09 million for the quarter, compared to analysts’ expectations of $5.25 million.
Large investors have recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Voyager Therapeutics by 15.8% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock worth $252,000 after buying an additional 1,794 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Voyager Therapeutics by 1.0% in the 1st quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock worth $890,000 after buying an additional 469 shares in the last quarter. Spark Investment Management LLC grew its holdings in Voyager Therapeutics by 18.5% in the 1st quarter. Spark Investment Management LLC now owns 146,200 shares of the company’s stock worth $2,798,000 after buying an additional 22,800 shares in the last quarter. Bank of America Corp DE grew its holdings in Voyager Therapeutics by 211.0% in the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock worth $100,000 after buying an additional 7,217 shares in the last quarter. Finally, Bailard Inc. bought a new position in Voyager Therapeutics in the 2nd quarter worth approximately $1,116,000. 75.39% of the stock is owned by institutional investors.
NASDAQ VYGR traded down $0.83 on Monday, hitting $19.65. 337,108 shares of the stock traded hands, compared to its average volume of 389,768. The stock has a 50-day moving average of $22.99 and a 200 day moving average of $20.89. Voyager Therapeutics has a twelve month low of $7.76 and a twelve month high of $28.79. The company has a market capitalization of $782.26 million, a P/E ratio of -7.15 and a beta of 2.55.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Read More: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.